Organoid models : the future companions of personalized drug development
© 2024 IOP Publishing Ltd..
High failure rates of the current drug development process are driving exemplary changes toward methodologies centered on human disease in-vitro modeling. Organoids are self-organized tissue sub-units resembling their organ of origin and are widely acknowledged for their unique potential in recapitulating human physio-pathological mechanisms. They are transformative for human health by becoming the platform of choice to probe disease mechanisms and advance new therapies. Furthermore, the compounds' validation as therapeutics represents another point of the drug development pipeline where organoids may provide key understandings and help pharma organizations replace or reduce animal research. In this review, we focus on gastrointestinal organoid models, which are currently the most advanced organoid models in drug development. We focus on experimental validations of their value, and we propose avenues to enhance their use in drug discovery anddevelopment, as well as precision medicine and diagnostics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Biofabrication - (2024) vom: 12. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Piraino, Francesco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3D cell culture |
|---|
| Anmerkungen: |
Date Revised 12.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1088/1758-5090/ad3e30 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370977696 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370977696 | ||
| 003 | DE-627 | ||
| 005 | 20240413233028.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1088/1758-5090/ad3e30 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1374.xml |
| 035 | |a (DE-627)NLM370977696 | ||
| 035 | |a (NLM)38608454 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Piraino, Francesco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Organoid models |b the future companions of personalized drug development |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 IOP Publishing Ltd. | ||
| 520 | |a High failure rates of the current drug development process are driving exemplary changes toward methodologies centered on human disease in-vitro modeling. Organoids are self-organized tissue sub-units resembling their organ of origin and are widely acknowledged for their unique potential in recapitulating human physio-pathological mechanisms. They are transformative for human health by becoming the platform of choice to probe disease mechanisms and advance new therapies. Furthermore, the compounds' validation as therapeutics represents another point of the drug development pipeline where organoids may provide key understandings and help pharma organizations replace or reduce animal research. In this review, we focus on gastrointestinal organoid models, which are currently the most advanced organoid models in drug development. We focus on experimental validations of their value, and we propose avenues to enhance their use in drug discovery anddevelopment, as well as precision medicine and diagnostics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 3D cell culture | |
| 650 | 4 | |a diagnostics | |
| 650 | 4 | |a disease modelling | |
| 650 | 4 | |a drug development | |
| 650 | 4 | |a drug discovery | |
| 650 | 4 | |a organoids | |
| 650 | 4 | |a perfusable organoids | |
| 700 | 1 | |a Costa, Mariana |e verfasserin |4 aut | |
| 700 | 1 | |a Meyer, Marine |e verfasserin |4 aut | |
| 700 | 1 | |a Cornish, Georgina |e verfasserin |4 aut | |
| 700 | 1 | |a Ceroni, Camilla |e verfasserin |4 aut | |
| 700 | 1 | |a Garnier, Virginie Marie Victoria Mangénie |e verfasserin |4 aut | |
| 700 | 1 | |a Hoehnel-Ka, Sylke |e verfasserin |4 aut | |
| 700 | 1 | |a Brandenberg, Nathalie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biofabrication |d 2009 |g (2024) vom: 12. Apr. |w (DE-627)NLM199859019 |x 1758-5090 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:12 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1088/1758-5090/ad3e30 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 12 |c 04 | ||